Johnson & Johnson
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a JNJ research report →
About the company
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
- CEO
- Joaquin Duato
- IPO
- 1962
- Employees
- 141,700
- HQ
- New Brunswick, NJ, US
Price Chart
- Market Cap
- $633.20B
- P/E
- 30.34
- P/S
- 6.57
- P/B
- 7.92
- EV/EBITDA
- 19.90
- Div Yield
- 1.99%
- Gross Margin
- 69.12%
- Op Margin
- 26.87%
- Net Margin
- 21.83%
- ROE
- 26.26%
- ROIC
- 13.60%
- Revenue
- $94.19B · 6.05%
- Net Income
- $26.80B · 90.56%
- EPS
- $11.03 · 88.87%
- Op Income
- $25.60B
- FCF YoY
- -0.73%
- 52W High
- $263.10
- 52W Low
- $154.21
- 50D MA
- $232.74
- 200D MA
- $218.94
- Beta
- 0.23
- Avg Volume
- 8.14M
Get TickerSpark's AI analysis on JNJ
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 11, 26 | Wengel Kathryn E | other | 10,000 |
| Jun 11, 26 | Wengel Kathryn E | sell | 10,000 |
| Jun 11, 26 | Wengel Kathryn E | other | 10,000 |
| Jun 9, 26 | Woods Eugene A. | other | 161.089 |
| Jun 9, 26 | Pinto Daniel E | other | 134.241 |
| Jun 9, 26 | HEWSON MARILLYN A | other | 214.786 |
| May 1, 26 | REED JOHN C | other | 25,255 |
| May 1, 26 | REED JOHN C | other | 11,002 |
| May 1, 26 | REED JOHN C | other | 25,255 |
| Apr 23, 26 | Woods Eugene A. | other | 975 |
Our JNJ coverage
Recent articles, reports, and earnings notes.
Eli Lilly is turning obesity demand into an access story now
Eli Lilly's next move looks less like a pipeline trade and more like an access trade. Demand was never the problem; broader PBM coverage and expected Medicare access starting July 1 make the revenue conversion story more immediate.
Healthcare’s breakout is a warning that the market is paying less for duration
Healthcare’s leadership over tech and semis looks less like a defensive flinch and more like a valuation message from a still-hawkish market. With rates staying restrictive, investors are rewarding nearer-term earnings durability and demanding a higher bar for crowded long-duration growth.
Inside Our Top Dividend Kings Stock Picks for 2026
These seven Dividend Kings combine long payout streaks with durable businesses, but McDonald’s, Procter & Gamble, and Colgate stand out most on overall quality.
Want a deeper read on JNJ?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.